Structure Therapeutics reported positive Phase II ACCESS results for aleniglipron, an oral GLP‑1 candidate, triggering a >100% jump in its share price. The company disclosed placebo‑adjusted weight loss of roughly 11% at the 120 mg dose at 36 weeks, data that investors viewed as competitive with larger players’ oral GLP‑1 programs. The readout intensifies competition among oral obesity pills, where Novo Nordisk and Eli Lilly are advancing high‑profile candidates. Analysts note the commercial prize is large if safety, tolerability, and manufacturing scale are proven; regulators will focus on cardiovascular outcomes and drug‑drug interactions as programs progress.